DOCSLIB.ORG

Humanized Anti-Her2/Neu (Herceptin/ Trastuzumab) ELISA Kit #200-510-HLG

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Humanized Anti-Her2/Neu (Herceptin/ Trastuzumab) ELISA Kit #200-510-HLG Humanized Anti-Her2/neu (Herceptin/ trastuzumab) ELISA Kit #200-510-HLG HER2 (Human Epidermal Growth Factor Receptor 2) also known as consequently has been extensively investigated. Neu, ErbB-2, CD340 (cluster of differentiation 340) or p185 is a protein HER2 is the target of the monoclonal that in humans is encoded by the ERBB2 gene. Neu is so named antibody trastuzumab (Herceptin). because it was derived from a rodent glioblastoma cell line, a type of Trastuzumab is effective only in cancers neural tumor. HER2 is named because it has a similar structure to where HER2 is over-expressed. human epidermal growth factor receptor, or HER1. HER2 is a member Herceptin is fully humanized mab (IgG1 of the epidermal growth factor receptor (EGFR/ErbB) family. kappa) produced in CHO cell culture. It Amplification or over-expression of this gene has been shown to play binds to the domain IV of the an important role in the pathogenesis and progression of certain extracellular segment of the HER2/neu aggressive types of breast cancer and in recent years it has evolved to receptor. Trastuzumab has had a major become an important biomarker and target of therapy for the disease. impact in the treatment of HER2-positive metastatic breast cancer. The The ErbB family is composed of four plasma membrane-bound combination of Trastuzumab with receptor tyrosine kinases. All four contain an extracellular ligand chemotherapy has been shown to binding domain, a transmembrane domain, and an intracellular domain increase both survival and response rate, in comparison to that can interact with a multitude of signaling molecules. Unlike the Trastuzumab alone. Herceptin costs about $100,000 for a full other family members, HER2 is considered to be an orphan receptor treatment. Another monoclonal antibody, Pertuzumab (2c4 or as it has no known ligand. HER2 can heterodimerise with any of the Omnitrag), which inhibits dimerization of HER2 and HER3 receptors, other three receptors. Dimerisation results in the autophosphorylation is in advanced clinical trials. Other approaches such as DNA-based of tyrosine residues within the cytoplasmic domain of the receptors and vaccines against Her2 using either the full length expression of her2 initiates a variety of signaling pathways. Signaling through the ErbB (pE2A) or extracellular domain or intracellular domains (pE2TM, family of receptors promotes cell proliferation and opposes apoptosis, pSec2, p185 or MVA-BN-Her2) are being used to produce antibodies and therefore must be tightly regulated to prevent uncontrolled cell to Her2. Similarly, Her 2 peptide-derived vaccine (E75, GP2, AE37 growth from occurring. peptide or multiple peptides) are being used as vaccine. Amplification or over-expression of the ERBB2 gene occurs in Like many humanized antibodies, Herceptin can antibodies or human approximately 30% of breast cancers. It is strongly associated with anti-human antibodies (HAHA). However, this is highly dependent increased disease recurrence and a worse prognosis. Over-expression upon the sensitivity of the assay. ADI has developed new ELISA kits is also known to occur in ovarian, stomach, and aggressive forms of that measures “Free Hercpetin” in patients treated with Herceptin. uterine cancer, such as uterine serous endometrial carcinoma. The ADI has also developed ELISA kits to detect antibodies to Herceptin extracellular domain of HER2 can be shed from the surface of tumour (Human Anti- Herceptin Antibodies) in patients receiving long-term cells and enter the circulation. HER2 testing is performed in breast treatments. These kits will allow to research better ways to monitor cancer patients to assess prognosis and to determine suitability for Herceptin treatment. Additional ELISA kits are available to monitor the Herceptin therapy. It is important that Herceptin is restricted to HER2- increase other autoimmune diseases (ANA, anti-dsDNA IgGs, positive individuals as it is expensive and has been associated with tuberculosis). ADI also have variety of antibodies to human, mouse, cardiac toxicity. Measurement of serum HER2 by ELISA offers a far and rat Herceptin and Her2 peptides for vaccine studies. less invasive method of determining HER2 status than a biopsy and Human Anti-Herceptin/Trasuzumab IgG (HAHA/HADA) ELISA Kit #200-520-HAG 3 ELISA Kit Features A 2.5 Herceptin coated, pre-coated, stabilized, ready-to-use 96-well strip plate, suitable for 2 multiple runs over 6-12 months. 4 1.5 Anti-Herceptin standards IgG (0-200 U/ml; Lot sp concn on the vial). 5 1 Sample size 100 ul (serum or plasma diluted ~1:100 or more). 0 0.5 0 105 minutes, 3 incubation steps at room temp 0 50 100 150 200 Sensitivity ~ 5 U/ml; Good Recovery and Assay Precision. Typical Anti-Herceptin Contains all necessary reagents. Shelf life ~6 months. Ig's (U/ml) This kit detects only the antibodies to Herceptin and not just human anti-human IgG (HAHA) or antibodies to regular human IgG. This kit measure all anti-Herceptin binding antibodies (IgG, IgM or IgA etc). In vitro research use only. List of Herceptin Related reagents and ELISAs available from ADI. Catalog# Product Description 200-510-HLG Herceptin/Trasuzumab ELISA Kit for human, 96 tests 200-520-HAG Human Anti-Herceptin/Trasuzumab Antibody (HAHA) ELISA Kit 96 tests 200-530-HER Her2/neu/Erbb2/CD340 protein ELISA kit, 96 tests ADI is also offering custom testing of animal or human samples for Herceptin or antibodies to Herceptin measurements. 200-520-HAG-Flr Rev. 121213 Alpha Diagnostic Intl Inc., 6203 Woodlake Center Dr, San Antonio, TX 78244, USA; Email: [email protected] (800) 786-5777; (210) 561-9515; Fax: (210) 561-9544; Web Site: www.4adi.com .
Load more

Recommended publications
  • CD137 Microbead Kit CD137 Microbead + Cells
    CD137 MicroBead Kit human Order no. 130-093-476 Contents 1.2 Background information 1. Description The activation-induced antigen CD137 (4-1BB) is a 30 kDa glycoprotein of the tumor necrosis factor (TNF) receptor 1.1 Principle of the MACS® Separation + + superfamily. It is mainly expressed on activated CD4 and CD8 1.2 Background information T cells, activated B cells, and natural killer cells, but can also be 1.3 Applications found on resting monocytes and dendritic cells. As a costimulatory molecule, CD137 is involved in the activation 1.4 Reagent and instrument requirements and survival of CD4, CD8, and NK cells. Its engagement enhances 2. Protocol expansion of T cells and activates them to secrete cytokines. CD137 has been described to be a suitable marker for antigen- 2.1 Sample preparation specific activation of human CD8+ T cells, as CD137 is not expressed 2.2 Magnetic labeling on resting CD8+ T cells and its expression is reliably induced after 2.3 Magnetic separation 24 hours of stimulation.¹,² 3. Example of a separation using the CD137 MicroBead Kit 1.3 Applications 4. References ● Enrichment of CD137+ T cells for phenotypical and functional 5. Appendix characterization. ● Enrichment of activated antigen-specific T cells after antigen- Warnings specific stimulation. Reagents contain sodium azide. Under acidic conditions sodium 1.4 Reagent and instrument requirements azide yields hydrazoic acid, which is extremely toxic. Azide ● compounds should be diluted with running water before discarding. Buffer: Prepare a solution containing phosphate-buffered These precautions are recommended to avoid deposits in plumbing saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), where explosive conditions may develop.
    [Show full text]
  • Human B Cell Isolation Product Selection Diagram
    Human B Cell Isolation Product Selection Explore the infographic below to find the correct human B cell isolation product for your application. 1. Your Starting Sample Whole Peripheral Blood/Buffy Coat PBMCs/Leukapheresis Pack 2. Cell Separation Platform Immunodensity Cell Separation Immunomagnetic Cell Separation Immunomagnetic Cell Separation 3. Product Line RosetteSep™ EasySep™ EasySep™ Sequential Selection Negative Selection Negative Selection Positive Selection Negative Selection Positive Selection 4. Selection Method (Positive + Negative) iRosetteSep™ HLA iEasySep™ Direct HLA i, iiEasySep™ HLA iEasySep™ HLA B Cell viEasySep™ Human CD19 EasySep™ Human IgG+ B Cell Enrichment Cocktail B Cell Isolation Kit Chimerism Whole Blood Enrichment Kit Positive Selection Kit II Memory B Cell Isolation (15064HLA)1, 2, 3 (89684) / EasySep™ Direct B Cell Positive Selection (19054HLA)1, 2 (17854)1, 2 Kit (17868)1 (optional), 2' HLA Crossmatch B Cell Kit (17886)1, 2 Isolation Kit (19684 - 1, 2 RosetteSep™ Human available in the US only) iiiEasySep™ Human B Cell viEasySep™ Release EasySep™ Human Memory 5. Cell Isolation Kits B Cell Enrichment Cocktail i, iiEasySep™ HLA Enrichment Kit Human CD19 Positive B Cell Isolation Kit 1, 2, 3 1, 2 1, 2 1 (optional), 2 Catalog #s shown in ( ) (15024) Chimerism Whole Blood (19054) Selection Kit (17754) (17864) EasySep™ Direct Human CD19 Positive Selection B-CLL Cell Isolation Kit Kit (17874)1, 2 1, 2, 3, 4 *RosetteSep™ Human (19664) iiiEasySep™ Human B Cell EasySep™ Human CD138 Multiple Myeloma Cell Isolation Kit
    [Show full text]
  • CD134 (OX40) Antibodies, Human for Research Use Only
    CD134 (OX40) antibodies, human For research use only One test corresponds to labeling of up to 107 cells in a total volume of 100 µL. Product Content Order no. CD134 (OX40)­VioBright FITC for 30 tests 130­109­664 CD134 (OX40)­VioBright FITC for 100 tests 130­109­605 CD134 (OX40)­PE for 30 tests 130­109­660 CD134 (OX40)­PE for 100 tests 130­109­601 CD134 (OX40)­APC for 30 tests 130­109­661 CD134 (OX40)­APC for 100 tests 130­109­602 CD134 (OX40)­PE­Vio770 for 30 tests 130­109­662 CD134 (OX40)­PE­Vio770 for 100 tests 130­109­603 CD134 (OX40)­APC­Vio770 for 30 tests 130­109­663 CD134 (OX40)­APC­Vio770 for 100 tests 130­109­604 CD134 (OX40)­Biotin for 30 tests 130­109­659 CD134 (OX40)­Biotin for 100 tests 130­109­600 Warnings Reagents contain sodium azide. Under acidic conditions sodium azide yields hydrazoic acid, which is extremely toxic. Azide compounds should be diluted with running water before discarding. These precautions are recommended to avoid deposits in plumbing where explosive conditions may develop. Technical data and background information Antigen CD134 (OX40) Clone REA621 Isotype recombinant human IgG1 Isotype control REA Control (S) antibodies Alternative names of antigen OX­40, OX40 Molecular mass of antigen [kDa] 27 Distribution of antigen B cells, endothelial cells, fibroblasts, lymphocytes, T cells Product format Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide. Fixation Cells should be stained prior to fixation, if formaldehyde is used as a fixative. Storage Store protected from light at 2–8 °C.
    [Show full text]
  • Due to Interleukin-6 Type Cytokine Redundancy Only Glycoprotein 130 Receptor Blockade Efficiently Inhibits Myeloma Growth
    Plasma Cell Disorders SUPPLEMENTARY APPENDIX Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth Renate Burger, 1 Andreas Günther, 1 Katja Klausz, 1 Matthias Staudinger, 1 Matthias Peipp, 1 Eva Maria Murga Penas, 2 Stefan Rose-John, 3 John Wijdenes 4 and Martin Gramatzki 1 1Division of Stem Cell Transplantation and Immunotherapy, Department of Internal Medicine II, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany; 2Institute of Human Genetics, Christian-Albrechts-University Kiel and Uni - versity Medical Center Schleswig-Holstein, Kiel, Germany; 3Department of Biochemistry, Christian-Albrechts-University of Kiel, Medical Faculty, Germany and 4Gen-Probe/Diaclone SAS, Besançon, France ©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2016.145060 Received: February 25, 2016. Accepted: September 14, 2016. Pre-published: September 22, 2016. Correspondence: [email protected] SUPPLEMENTARY METHODS Cell lines and culture Cell lines INA-6, INA-6.Tu1 and B9 were cultivated in RPMI-1640 with GlutaMax™-I, 25 mM HEPES (Gibco®/Life Technologies GmbH, Darmstadt, Germany), 10% (v/v) heat-inactivated fetal bovine serum (FBS) (HyClone; Perbio Science, Erembodegen, Belgium), and antibiotics (R10+ medium) supplemented with 2.5 ng/ml recombinant huIL-6 (Gibco®/Life Technologies GmbH, Darmstadt, Germany). The cell lines are routinely confirmed to be negative for mycoplasma contamination (Venor™GeM Mycoplasma Detection Kit, Sigma-Aldrich, St. Louis, MO). Cytokines and other reagents Recombinant huIL-6 was purchased from Gibco®/Life Technologies (Darmstadt, Germany), huLIF was from Reliatech (Wolfenbüttel, Germany). Recombinant muIL-6 was obtained from Peprotech (Rocky Hill, NJ), and soluble muIL-6R was from R&D Systems (Minneapolis, MN).
    [Show full text]
  • Induces Antigen Presentation in B Cells Cell-Activating Factor of The
    B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells This information is current as of September 27, 2021. Min Yang, Hidenori Hase, Diana Legarda-Addison, Leena Varughese, Brian Seed and Adrian T. Ting J Immunol 2005; 175:2814-2824; ; doi: 10.4049/jimmunol.175.5.2814 http://www.jimmunol.org/content/175/5/2814 Downloaded from References This article cites 54 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/175/5/2814.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 Min Yang,* Hidenori Hase,* Diana Legarda-Addison,* Leena Varughese,* Brian Seed,† and Adrian T.
    [Show full text]
  • Updated November 2019 KIT Mutation the KIT Gene Is Associated With
    Updated November 2019 KIT Mutation The KIT gene is associated with autosomal dominant piebaldism, gastrointestinal stromal tumors (GISTs), and familial mastocytosis.1-3 The type of mutation identified in the KIT gene determines the symptoms/cancer risks that the individual may have. Pathogenic loss-of-function (LOF) mutations in the KIT gene are generally only associated with Piebaldism. However, pathogenic gain of function mutations in the KIT gene are associated with systemic mastocytosis and gastrointestinal stromal tumors.4,5 Piebaldism: This is a rare condition characterized by the patchy absence of melanocytes in certain areas of the skin and hair. Melanocytes produce the pigment melanin, which contributes to hair, eye, and skin color. The absence of melanocytes leads to patches of skin and hair that are lighter than normal. These unpigmented areas are typically present at birth and do not increase in size or number.6-8 Gastrointestinal stromal tumors (GIST): GISTs are tumors that occur in the gastrointestinal tract, most commonly in the stomach or small intestine. Small tumors may cause no signs or symptoms. However, some people with GISTs may experience pain or swelling in the abdomen, nausea, vomiting, loss of appetite, or weight loss. These tumors can be cancerous (malignant) or noncancerous (benign). Mastocytosis: This is a blood disorder that occurs when white blood cells called mast cells accumulate in one or more tissues (most commonly in the bone marrow). Mast cells normally trigger inflammation during an allergic reaction. When an environmental trigger activates mast cells, they release proteins that signal an immune response. In systemic mastocytosis, excess mast cells mean more proteins are being released in the tissues where the cells accumulate, leading to an increased immune response.
    [Show full text]
  • Human Scd137 (4-1BB) ELISA
    Human sCD137 (4-1BB) ELISA Kit Instruction Manual Cat.No. PK-EL-66556 2 Instruction Manual Contents 1. Intended Use 3 2. Summary 3 3. Principles of the Test 4 4. Reagents Provided 5 5. Storage Instructions – ELISA Kit 6 6. Specimen Collection and Storage Instructions 6 7. Materials Required But Not Provided 7 8. Precautions for Use 7 9. Preparation of Reagents 9 10. Test Protocol 12 11. Calculation of Results 16 12. Limitations 19 13. Performance Characteristics 19 14. Bibliography 23 15. Reagent Preparation Summary 25 16. Test Protocol Summary 26 17. Ordering Information 27 Instruction Manual 3 1. Intended Use The human sCD137 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human sCD137. The human sCD137 ELISA is for research use only. Not for diagnostic or therapeutic procedures. 2. Summary CD137 (ILA/4-1BB) is a member of the tumor necrosis factor receptor family (6), expressed on activated T lymphocytes (1, 11). The expression of CD137 is strictly activation dependent in primary cells (4). Co- stimulation through CD137 enhances T lymphocyte activation and may enable rejection of tumors in vivo (3, 7, 2). The gene for human CD137 resides on chromosome 1q36, in a cluster of related genes, and this chromosomal region is associated with mutations in several malignancies (9). Bidirectional signalling has been demonstrated for the CD137 receptor/ ligand system. While cross-linking of CD137 activates T lymphocytes, cross-linking of the CD137 ligand has the opposite effect. This reverse signalling through the CD137 ligand inhibits proliferation of T lymphocytes and induces programmed cell death (10).
    [Show full text]
  • Misfolded Proteins Bind and Activate Death Receptor 5 to Trigger
    RESEARCH ARTICLE Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress Mable Lam1,2, Scot A Marsters3, Avi Ashkenazi3*, Peter Walter1,2* 1Department of Biochemistry and Biophysics, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States; 2Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States; 3Cancer Immunology, Genentech, Inc, San Francisco, United States Abstract Disruption of protein folding in the endoplasmic reticulum (ER) activates the unfolded protein response (UPR)—a signaling network that ultimately determines cell fate. Initially, UPR signaling aims at cytoprotection and restoration of ER homeostasis; that failing, it drives apoptotic cell death. ER stress initiates apoptosis through intracellular activation of death receptor 5 (DR5) independent of its canonical extracellular ligand Apo2L/TRAIL; however, the mechanism underlying DR5 activation is unknown. In cultured human cells, we find that misfolded proteins can directly engage with DR5 in the ER-Golgi intermediate compartment, where DR5 assembles pro-apoptotic caspase 8-activating complexes. Moreover, peptides used as a proxy for exposed misfolded protein chains selectively bind to the purified DR5 ectodomain and induce its oligomerization. These findings indicate that misfolded proteins can act as ligands to activate DR5 intracellularly and promote apoptosis. We propose that cells can use DR5 as a late protein-folding checkpoint before committing to a terminal apoptotic fate. *For correspondence: [email protected] (AA); [email protected] (PW) Introduction Competing interest: See Proper folding of transmembrane and secreted proteins is critical to cell function and intercellular page 24 communication.
    [Show full text]
  • Human CD134 / OX40 ELISA Kit (ARG81808)
    Product datasheet [email protected] ARG81808 Package: 96 wells Human CD134 / OX40 ELISA Kit Store at: 4°C Component Cat. No. Component Name Package Temp ARG81808-001 Antibody-coated 8 X 12 strips 4°C. Unused strips microplate should be sealed tightly in the air-tight pouch. ARG81808-002 Standard 2 X 10 ng/vial 4°C ARG81808-003 Standard/Sample 30 ml (Ready to use) 4°C diluent ARG81808-004 Antibody conjugate 1 vial (100 µl) 4°C concentrate (100X) ARG81808-005 Antibody diluent 12 ml (Ready to use) 4°C buffer ARG81808-006 HRP-Streptavidin 1 vial (100 µl) 4°C concentrate (100X) ARG81808-007 HRP-Streptavidin 12 ml (Ready to use) 4°C diluent buffer ARG81808-008 25X Wash buffer 20 ml 4°C ARG81808-009 TMB substrate 10 ml (Ready to use) 4°C (Protect from light) ARG81808-010 STOP solution 10 ml (Ready to use) 4°C ARG81808-011 Plate sealer 4 strips Room temperature Summary Product Description ARG81808 Human CD134 / OX40 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human CD134 / OX40 in serum, plasma (heparin, EDTA) and cell culture supernatants. Tested Reactivity Hu Tested Application ELISA Specificity There is no detectable cross-reactivity with other relevant proteins. Target Name CD134 / OX40 Conjugation HRP Conjugation Note Substrate: TMB and read at 450 nm. Sensitivity 15.6 pg/ml Sample Type Serum, plasma (heparin, EDTA) and cell culture supernatants. Standard Range 31.2 - 2000 pg/ml Sample Volume 100 µl www.arigobio.com 1/2 Precision Intra-Assay CV: 6.3%; Inter-Assay CV: 7.7% Alternate Names CD134; TAX transcriptionally-activated glycoprotein 1 receptor; TXGP1L; OX40L receptor; Tumor necrosis factor receptor superfamily member 4; OX40; CD antigen CD134; IMD16; ACT35 antigen; ACT35 Application Instructions Assay Time ~ 5 hours Properties Form 96 well Storage instruction Store the kit at 2-8°C.
    [Show full text]
  • Human CD30 ELISA Kit (ARG81684)
    Product datasheet [email protected] ARG81684 Package: 96 wells Human CD30 ELISA Kit Store at: 4°C Component Cat. No. Component Name Package Temp ARG81684-001 Antibody-coated 8 X 12 strips 4°C. Unused strips microplate should be sealed tightly in the air-tight pouch. ARG81684-002 Standard 2 X 10 ng/vial 4°C ARG81684-003 Standard/Sample 30 ml (Ready to use) 4°C diluent ARG81684-004 Antibody conjugate 1 vial (100 µl) 4°C concentrate (100X) ARG81684-005 Antibody diluent 12 ml (Ready to use) 4°C buffer ARG81684-006 HRP-Streptavidin 1 vial (100 µl) 4°C concentrate (100X) ARG81684-007 HRP-Streptavidin 12 ml (Ready to use) 4°C diluent buffer ARG81684-008 25X Wash buffer 20 ml 4°C ARG81684-009 TMB substrate 10 ml (Ready to use) 4°C (Protect from light) ARG81684-010 STOP solution 10 ml (Ready to use) 4°C ARG81684-011 Plate sealer 4 strips Room temperature Summary Product Description ARG81684 Human CD30 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human CD30 in serum, plasma (heparin, EDTA) and cell culture supernatants. Tested Reactivity Hu Tested Application ELISA Specificity There is no detectable cross-reactivity with other relevant proteins. Target Name CD30 Conjugation HRP Conjugation Note Substrate: TMB and read at 450 nm. Sensitivity 78 pg/ml Sample Type Serum, plasma (heparin, EDTA) and cell culture supernatants. Standard Range 156 - 10000 pg/ml Sample Volume 100 µl www.arigobio.com 1/2 Precision Intra-Assay CV: 5.6%; Inter-Assay CV: 7.2% Alternate Names Tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30; Ki-1; Lymphocyte activation antigen CD30; CD antigen CD30; D1S166E; CD30L receptor Application Instructions Assay Time ~ 5 hours Properties Form 96 well Storage instruction Store the kit at 2-8°C.
    [Show full text]
  • C-Kit Gene Mutations in Adenoid Cystic Carcinoma Are Rare
    Modern Pathology (2010) 23, 905–907 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 905 c-kit gene mutations in adenoid cystic carcinoma are rare Modern Pathology (2010) 23, 905–906; doi:10.1038/modpathol.2010.61 To the Editor: It was with great surprise that we read Vila et al thus further points to the possibility of the article entitled ‘Identification of c-kit gene technical artifact. The authors described their mutations in primary adenoid cystic carcinoma of technique as ‘more sensitive’ than those used in the salivary gland’ by Vila et al,1 who purported to other studies, but, in contrast, we believe the show a high rate (7/8, 88%) of activating c-kit gene previous studies were designed and controlled to mutations mainly in exon 11. In the study published prevent artifact and were perfectly adequate to in 1999 that first identified KIT as an up-regulated detect mutations that were present in the majority gene product in adenoid cystic carcinoma (ACC), of tumor cells in tissue samples. exons 11 and 17 of c-kit were sequenced in 28 cases The authors characterized the data in the litera- from the University of Virginia and no activating ture regarding the activity of KIT antagonists in mutations were found.2 This study used sequencing treating patients with ACC as ‘conflicting’. We, of total PCR products to help obviate the detection of however, argue that, except for two anecdotal PCR artifacts, and the samples were macrodissected studies that they cite,9 the published data from and histologically verified to ensure that tumor cells prospective clinical studies examining the role of comprised the majority of the sample.
    [Show full text]
  • FAS-Antisense 1 Lncrna and Production of Soluble Versus Membrane Fas in B-Cell Lymphoma
    Leukemia (2014) 28, 2376–2387 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma L Sehgal, R Mathur, FK Braun, JF Wise, Z Berkova, S Neelapu, LW Kwak and F Samaniego Impaired Fas-mediated apoptosis is associated with poor clinical outcomes and cancer chemoresistance. Soluble Fas receptor (sFas), produced by skipping of exon 6, inhibits apoptosis by sequestering Fas ligand. Serum sFas is associated with poor prognosis of non-Hodgkin’s lymphomas. We found that the alternative splicing of Fas in lymphomas is tightly regulated by a long-noncoding RNA corresponding to an antisense transcript of Fas (FAS-AS1). Levels of FAS-AS1 correlate inversely with production of sFas, and FAS-AS1 binding to the RBM5 inhibits RBM5-mediated exon 6 skipping. EZH2, often mutated or overexpressed in lymphomas, hyper-methylates the FAS-AS1 promoter and represses the FAS-AS1 expression. EZH2-mediated repression of FAS-AS1 promoter can be released by DZNeP (3-Deazaneplanocin A) or overcome by ectopic expression of FAS-AS1, both of which increase levels of FAS-AS1 and correspondingly decrease expression of sFas. Treatment with Bruton’s tyrosine kinase inhibitor or EZH2 knockdown decreases the levels of EZH2, RBM5 and sFas, thereby enhancing Fas-mediated apoptosis. This is the first report showing functional regulation of Fas repression by its antisense RNA. Our results reveal new therapeutic targets in lymphomas and provide a rationale for the use of EZH2 inhibitors or ibrutinib in combination with chemotherapeutic agents that recruit Fas for effective cell killing.
    [Show full text]